Expert Review of Vaccines (Dec 2023)

Vaccine development for pathogenic fungi: current status and future directions

  • Jéssica L. Chechi,
  • Felipe A. C. da Costa,
  • Julia M. Figueiredo,
  • Cássia M. de Souza,
  • Alessandro F. Valdez,
  • Daniel Zamith-Miranda,
  • Aline C. Camara,
  • Carlos P. Taborda,
  • Joshua D. Nosanchuk

DOI
https://doi.org/10.1080/14760584.2023.2279570
Journal volume & issue
Vol. 22, no. 1
pp. 1136 – 1153

Abstract

Read online

ABSTRACTIntroduction Fungal infections are caused by a broad range of pathogenic fungi that are found worldwide with different geographic distributions, incidences, and mortality rates. Considering that there are relatively few approved medications available for combating fungal diseases and no vaccine formulation commercially available, multiple groups are searching for new antifungal drugs, examining drugs for repurposing and developing antifungal vaccines, in order to control deaths, sequels, and the spread of these complex infections.Areas covered This review provides a summary of advances in fungal vaccine studies and the different approaches under development, such as subunit vaccines, whole organism vaccines, and DNA vaccines, as well as studies that optimize the use of adjuvants. We conducted a literature search of the PubMed with terms: fungal vaccines and genus of fungal pathogens (Cryptococcus spp. Candida spp. Coccidioides spp. Aspergillus spp. Sporothrix spp. Histoplasma spp. Paracoccidioides spp. Pneumocystis spp. and the Mucorales order), a total of 177 articles were collected from database.Expert opinion Problems regarding the immune response development in an immunocompromised organism, the similarity between fungal and mammalian cells, and the lack of attention by health organizations to fungal infections are closely related to the fact that, at present, there are no fungal vaccines available for clinical use.

Keywords